Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2015 | Research

Potential risk of residual cancer cells in the surgical treatment of initially unresectable pancreatic carcinoma after chemoradiotherapy

Authors: Hironobu Takano, Takahiro Tsuchikawa, Toru Nakamura, Keisuke Okamura, Toshiaki Shichinohe, Satoshi Hirano

Published in: World Journal of Surgical Oncology | Issue 1/2015

Abstract

Background

With development of chemoradiotherapy for pancreatic carcinoma, borderline resectable or initially unresectable cases sometimes become operable after long-term intensive chemoradiotherapy. However, there is no established strategy for adjuvant surgery with respect to whether the surgical resection should be extensive or downsized accordingly with diminished disease areas following response to chemoradiotherapy.

Methods

The clinical and pathological aspects of 18 patients with initially unresectable pancreatic cancer who underwent adjuvant surgery after chemo(radio)therapy in our department from 2007 were evaluated.

Results

Overall survival from initial treatment was much better for patients with R0 resection than for patients with R1/2 resection. In two of three patients who had complete improvement of plexus (PL) invasion after chemo(radio)therapy, there had still remained pathological plexus invasion. It was shown that tumors did not shrink continuously from the tumor front, but parts remained discontinuously at the distal portion in the process of tumor regression by chemo(radio)therapy.

Conclusions

In adjuvant surgery for patients with locally advanced pancreatic cancer, the potential risk of residual cancer in the regression area following chemoradiotherapy should be considered. Achieving R0 resection will lead to an improved prognosis, and it is necessary to consider how well the extent of resection is after a favorable response to chemoradiotherapy.

Warshaw AL, Fernandez-del CC. Pancreatic carcinoma. N Engl J Med. 1992;326:455–65.PubMedCrossRef

Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer. 1995;31A(6):882–7.PubMedCrossRef

Lygidakis NJ, Ziras FA, Kyparidou E, Parissis J, Papadopoulou P, Venetsanou B. Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma. Hepatogastroenterology. 1995;42(6):1039–52.PubMed

Sho M, Akahori T, Tanaka T, Kinoshita T, Tamamoto T, Nomi T, et al. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2012;20(2):197–205.CrossRef

Strobel O, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, et al. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 2012;152:S33–42.PubMedCrossRef

Kato K, Kondo S, Hirano S, Tanaka E, Shichinohe T, Tsuchikawa T, et al. Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. J Hepatobiliary Pancreat Sci. 2011;18:712–6.PubMedCrossRef

Deyali C, Matthew H, Asif R, Hua W, Alina C, Gauri R, et al. Perineural and intra-neural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012;36:409–17.CrossRef

Deyali C, Matthew H, Asif R, Gauri R, Robert A, Hua W, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma. Cancer. 2012;118:3182–90.CrossRef

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef

10.

Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.PubMedCrossRef

11.

Childs DS, Moertel CG, Holbrook MA, Reitemeier RJ, Colby MY. Treatment of malignant neoplasms of the gastrointestinal tract with a combination of 5-fluorouracil and radiation. Radiology. 1965;84:843–8.PubMedCrossRef

12.

Hazel JJ, Thirwell MP, Huggins M, Maksymiuk A, MacFarlane JK. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol. 1981;32:164–5.PubMed

13.

Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373–8.PubMed

14.

Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–5.CrossRef

15.

Saif MW. New developments in the treatment of pancreatic cancer. Highlights from the “44th ASCO Annual Meeting”. Chicago, IL, USA. May 30–June 3, 2008. J Pancreas. 2008;9(4):391–7.

16.

Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, et al. Phase III trial comparing an intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.PubMedCrossRef

17.

Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.PubMedCentralPubMedCrossRef

18.

Gillmore R, Laurence V, Raouf S, Tobias J, Blackman G, Meyer T, et al. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. Clin Oncol. 2010;22:564–9.CrossRef

19.

Ogawa K, Ito Y, Hirokawa N, Shibuya K, Kokubo M, Ogo E, et al. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival. Int J Radiat Oncol Biol Phys. 2012;83(2):559–65.PubMedCrossRef

20.

Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20:590–600.PubMedCrossRef

21.

McVeigh TP, Al-Azawi D, Kearney DE, Malone C, Sweeney KJ, Barry K, et al. Assessing the impact of neoadjuvant chemotherapy on the management of the breast and axilla in breast cancer. Clin Breast Cancer. 2013;14:20–5.PubMedCrossRef

22.

Marín C, Robles R, López Conesa A, Torres J, Flores DP, Parrilla P. Outcome of strict patient selection for surgical treatment of hepatic and pulmonary metastases from colorectal cancer. Dis Colon Rectum. 2013;56:43–50.PubMedCrossRef

23.

Nakao A, Takeda S, Inoue S, Nomoto S, Kanazumi N, Sugimoto H, et al. Indications and techniques of extended resection for pancreatic cancer. World J Surg. 2006;30:976–82.PubMedCrossRef

24.

Kitagawa H, Ohta T, Tajima H, Nakagawara H, Makino I, Takamura H, et al. En bloc resection including the superior mesenteric artery and vein of locally advanced pancreatic carcinomas. J Jpn Surg Soc. 2011;112(3):164–9.

Title: Potential risk of residual cancer cells in the surgical treatment of initially unresectable pancreatic carcinoma after chemoradiotherapy
Authors: Hironobu Takano
Takahiro Tsuchikawa
Toru Nakamura
Keisuke Okamura
Toshiaki Shichinohe
Satoshi Hirano
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2015
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-015-0617-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Potential risk of residual cancer cells in the surgical treatment of initially unresectable pancreatic carcinoma after chemoradiotherapy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Ataxia induced by a thymic neuroblastoma in the elderly patient

Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients

Complete resolution of a calcifying cystic odontogenic tumor with physiological eruption of a dislocated permanent tooth after marsupialization in a child with a mixed dentition: a case report

Outcome using selective hemihepatic vascular occlusion and Pringle maneuver for hepatic resection of liver cavernous hemangioma

Common genetic polymorphisms in pre-microRNAs and risk of bladder cancer

Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma